All In Biotech

Drug Trial Radar · NCT06231550

A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

Mar 1, 2023

Primary completion

Mar 18, 2025

Study completion Mar 18, 2025

Sponsor

Sponsor type
Industry
First posted
Jan 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I clinical study to evaluate safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Axl inhibitor FC084CSA in patients with advanced malignant solid tumors who have failed standard anti-cancer treatment.

Conditions

  • Advanced Malignant Solid Tumors

Interventions

  • FC084CSA tabletsDrug

    FC084CSA accelerated doses at 100mg QD, and then started the conventional "3+3" design from 200mg QD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the Maximum Tolerated Dose (MTD)Time frame: Approximately 12 months
  2. Determine the Recommended Phase 2 Dose (RP2D)Time frame: Approximately 12 months
  3. Determine dose-limiting toxicity (DLT)Time frame: 24 days after first dose
  4. Frequency of adverse events (AEs) and SAEsTime frame: Approximately 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.